|
Kronos Bio Inc (NASDAQ: KRON) |
|
Kronos Bio Inc
KRON's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Kronos Bio Inc growth rates, revenue grew
by 158.45 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 486
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Kronos Bio Inc net loss decreased from $-31 millions, to $-14 millions in III. Quarter 2024,
• More on KRON's Growth
|
|
Kronos Bio Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 3.44 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 6.06.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.86.
• More on KRON's Valuation
|
|
|
|
|
Kronos Bio Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 3.44 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 6.06.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 4.86.
Kronos Bio Inc Price to Book Ratio is at 0.54 lower than Industry Avg. of 1623.08. and higher than S&P 500 Avg. of 0.01
• More on KRON's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com